Drug Information

Drug General Information
Drug ID
D0E1LB
Former ID
DIB009401
Drug Name
MK-2578
Indication Anemia [ICD9: 280-285; ICD10:D50-D64] Phase 2 [522772]
Company
Merck Bioventures
Target and Pathway
Target(s) Erythropoietin ligand Target Info Agonist [525376]
KEGG Pathway Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Pathway Interaction Database HIF-2-alpha transcription factor network
Signaling events mediated by Stem cell factor receptor (c-Kit)
EPO signaling pathway
HIF-1-alpha transcription factor network
Reactome Regulation of gene expression by Hypoxia-inducible Factor
WikiPathways EPO Receptor Signaling
Hematopoietic Stem Cell Differentiation
Differentiation Pathway
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
References
Ref 522772ClinicalTrials.gov (NCT00968617) A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002). U.S. National Institutes of Health.
Ref 525376Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636. doi: 10.1038/nbt0710-636a.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.